Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alterity Therapeutics Limited

3.50
+0.10002.94%
Post-market: 3.500.00000.00%16:07 EDT
Volume:9.07K
Turnover:31.01K
Market Cap:51.81M
PE:-2.38
High:3.50
Open:3.43
Low:3.31
Close:3.40
Loading ...

Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting

TIPRANKS
·
10 Apr

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

GlobeNewswire
·
10 Apr

3 Promising ASX Penny Stocks With Market Caps Over A$20M

Simply Wall St.
·
12 Mar

Alterity Therapeutics raises A$40M in placement

TIPRANKS
·
10 Feb

Alterity Therapeutics Raises A$40.0 million in Placement

GlobeNewswire
·
10 Feb

Alterity Therapeutics Ltd (ADR) trading halted, news pending

TIPRANKS
·
06 Feb

Benchmark Downgrades Alterity Therapeutics to Hold From Speculative Buy

MT Newswires Live
·
03 Feb

Alterity Therapeutics Is Maintained at Buy by Maxim Group

Dow Jones
·
31 Jan

Alterity Therapeutics (ASX:ATH) shareholder returns have been stellar, earning 260% in 1 year

Simply Wall St.
·
31 Jan

Sector Update: Health Care Stocks Gain in Afternoon Trading

MT Newswires Live
·
31 Jan

Top Midday Gainers

MT Newswires
·
31 Jan

Nasdaq Moves Lower; Meta Platforms Posts Strong Sales

Benzinga
·
31 Jan

Dow Jumps Over 100 Points; Tesla Earnings Miss Views

Benzinga
·
30 Jan

Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up

MT Newswires Live
·
30 Jan

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

GlobeNewswire
·
30 Jan

Alterity Therapeutics Ltd (ADR) trading halted, news pending

TIPRANKS
·
28 Jan

Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

GlobeNewswire
·
24 Jan

Alterity CEO says ‘filled with optimism for 2025’

TIPRANKS
·
09 Jan

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

GlobeNewswire
·
09 Jan

Alterity Therapeutics Initiated at Buy by Maxim Group

Dow Jones
·
13 Dec 2024